NCT00716287

Unknown

Characterisation of Gene Variants in the Angiogenic Pathway

National University Hospital, Singapore Source

Compare

Other study identifiers

Sponsor study identifier

MC01/03/07

Study Type

observational

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

1

Timeline

Study Start

March 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2014

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

Not reported

Date not reported

Brief Summary

Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma. Somatic mutations in genes related to tumorigenesis have been associated with treatment response whereas germline gene variants have been associated with tumor risk, prognosis and treatment related toxicity.Study objectives are:

1.To characterise the prevalence and clinicopathological associations of germline and somatic variation in genes involved in the angiogenic pathway in healthy donors and unselected cancer patients
2.To examine the association between angiogenic gene variants and outcome in patients receiving anti-angiogenic therapy

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 2007
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
July 15, 2008
Actual (reported)
First Posted
July 16, 2008
Actual (reported)
Primary Completion
December 2014
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: January 14, 2014
Status Verified: January 2014
Last Update Submitted: January 13, 2014

Conditions

Solid Tumors

Study Arms (1)

1

Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.

You may qualify if:

Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

National University Hospital, Singapore
Otherlead

Study Sites (1)

National University Hospital

Singapore, Singapore

Study Officials

Ross Andrew Soo, MBBS
National University Hospital, Singapore
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER

Study Record Dates

First Submitted

July 15, 2008

First Posted

July 16, 2008

Study Start

March 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2014

Estimated (date passed)

NCT01445106

A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors

Phase 1Completed

NCT00560716

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

Phase 1Terminated

NCT01702129

Anti-EGFR Immunoliposomes in Solid Tumors

Phase 1Completed

NCT00586560

Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)

Phase 1Completed

NCT00591292

Phase I Study in Advanced Solid Tumors

Phase 1Completed

NCT00448786

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Phase 1Completed

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

January 14, 2014

Record last verified: 2014-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00716287
Data provider: ClinicalTrials.gov
Source updated: 2014-01-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:54 UTC

Locations

SG(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Conditions

Study Arms (1)

1

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Study Design

Study Record Dates

Source record

Locations